After H.C. Wainwright and Chardan Capital gave Lineage Cell Therapeutics (NYSE MKT: LCTX) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Lineage Cell Therapeutics yesterday and set a price target of $3.00. The company’s shares closed last Monday at $0.78, close to its 52-week low of $0.66.
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -22.0% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Actinium Pharmaceuticals, and Inovio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lineage Cell Therapeutics with a $3.67 average price target, a 409.7% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $4.00 price target.
The company has a one-year high of $1.87 and a one-year low of $0.66. Currently, Lineage Cell Therapeutics has an average volume of 369.3K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LCTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer.